SHINE Technologies has completed the acquisition of the Lantheus SPECT portfolio and manufacturing facility while naming Michael Rossi as CEO of the new SHINE SPECT division...
SHINE is drawing renewed attention for its fusion-based isotope production as the US works to localize Mo-99 and reduce dependence on foreign reactors—an important shift for the nuclear medicine supply chain that underpins most diagnostic procedures...
Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, Medical Isotopes, NEWS, Nuclear competitiveness, Nuclear innovation, Nuclear R&D, Portfolio Venture, Private companies, US competitiveness, US technological leadership
Sign up to receive Nucleation Insights
For New Investors
For Donors & Advocates
For Current Investors
(Note: Must be logged in at AngelList)
Nucleation Direct Messages
Nucleation (Fund I) Posts
Your Portfolio Dashboard
Your Funding Page
How to Contact Us
